Quick Answer
BriaCell Therapeutics Corp. reported Net Income of -$26.31 million for fiscal year 2025.
BriaCell Therapeutics Corp. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$26.31M -449.1% |
-$4.79M +76.4% |
-$20.30M +24.4% |
-$26.84M -94.3% |
-$13.82M | — |
| Diluted EPS | -$62.19 -42.4% |
-$43.68 -3260.0% |
-$1.30 +24.9% |
-$1.73 | — | — |
| Total Assets | $21.65M +268.7% |
$5.87M -78.4% |
$27.16M -36.2% |
$42.58M -26.6% |
$58.04M | — |
| Cash and Equivalents | $10.49M +1117.3% |
$862.1K -95.9% |
$21.25M -48.2% |
$41.04M -28.3% |
$57.27M | — |
| Stockholders Equity | $17.33M +745.6% |
-$2.68M +28.9% |
-$3.78M -136.6% |
$10.33M -62.7% |
$27.67M +1109.6% |
-$2.74M |
| R&D Expense | $21.27M -21.7% |
$27.18M +77.2% |
$15.34M +91.2% |
$8.02M +296.9% |
$2.02M | — |
| Operating Income | -$27.20M +18.4% |
-$33.33M -43.2% |
-$23.27M -52.2% |
-$15.29M -119.2% |
-$6.98M | — |
| Shares Outstanding | 294,694 +141.7% |
121,907 -99.2% |
15.98M +3.0% |
15.52M +1.6% |
15.27M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | October 31, 2025 | -$8.20M | -41.3% | -33.8% |
| Diluted EPS | October 31, 2025 | -$4.35 | +86.7% | -165.2% |
| Total Assets | October 31, 2025 | $13.08M | +25.5% | -39.6% |
| Cash and Equivalents | October 31, 2025 | $2.71M | -53.1% | -74.1% |
| Stockholders Equity | October 31, 2025 | $9.35M | +151.8% | -46.1% |
| R&D Expense | October 31, 2025 | $6.68M | +82.3% | +38.9% |
| Operating Income | October 31, 2025 | -$8.32M | -61.5% | -31.5% |
| Shares Outstanding | August 31, 2025 | 1.88M | — | +0.0% |
- BriaCell Therapeutics Corp. reported Net Income of -$26.31 million for fiscal year 2025.
- BriaCell Therapeutics Corp. showed a decrease of -449.1% in Net Income compared to the prior fiscal year.
- BriaCell Therapeutics Corp. reported Diluted EPS of $62.19 per share (loss) for fiscal year 2025.
- BriaCell Therapeutics Corp. showed a decrease of -42.4% in Diluted EPS compared to the prior fiscal year.
- BriaCell Therapeutics Corp. reported Total Assets of $21.65 million for fiscal year 2025.
- BriaCell Therapeutics Corp. showed an increase of +268.7% in Total Assets compared to the prior fiscal year.
- BriaCell Therapeutics Corp. reported Cash and Equivalents of $10.49 million for fiscal year 2025.
- BriaCell Therapeutics Corp. showed an increase of +1117.3% in Cash and Equivalents compared to the prior fiscal year.
- BriaCell Therapeutics Corp. reported Stockholders Equity of $17.33 million for fiscal year 2025.
- BriaCell Therapeutics Corp. showed an increase of +745.6% in Stockholders Equity compared to the prior fiscal year.
- BriaCell Therapeutics Corp. reported R&D Expense of $21.27 million for fiscal year 2025.
- BriaCell Therapeutics Corp. showed a decrease of -21.7% in R&D Expense compared to the prior fiscal year.
- BriaCell Therapeutics Corp. reported Operating Income of -$27.20 million for fiscal year 2025.
- BriaCell Therapeutics Corp. showed an increase of +18.4% in Operating Income compared to the prior fiscal year.
- BriaCell Therapeutics Corp. reported Shares Outstanding of 1.88 million shares for fiscal year 2025.
- BriaCell Therapeutics Corp. showed an increase of +539.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: